Fiburik F / C tablet
Febuxostat
80mg
Neopharma
| Pack size | 30’s (10’s Blister × 3) |
|---|---|
| Dispensing mode | POM |
| Source | UAE |
| Agent | NEW MEDICAL CENTRE |
| Retail Price | 84.50 AED |
Available as:
Indications
Fiburik F / C tablet is used for:
Gout, Hyperuricemia
Adult Dose
Chronic Gout
40 mg/day PO initially; maintenance: 40-80 mg/day; increased if serum uric acid is >6 mg/mL after 2 weeks
Hepatic impairment
Mild to moderate (Child-Pugh class A or B): Dosage adjustment not necessary
Severe (Child-Pugh class C): Data not available; use with caution
Child Dose
Safety and efficacy not established
Renal Dose
Renal impairment
Mild to moderate (CrCl 30-89 mL/min): Dosage adjustment not necessary
Severe (CrCl <30 mL/min): Data not available; use with caution
Administration
May be taken with or without food. May be taken w/o regard to antacid use.
Contra Indications
Patients being treated with azathioprine, mercaptopurine, or theophylline.
Precautions
Cardiovascular death
Patients with established cardiovascular (CV) disease treated with febuxostat had a higher rate of CV death compared with those treated with allopurinol in a CV outcomes study.
Evaluate risks and benefits when prescribing febuxostat or continuing treatment.
Gout Flare: An increase in gout flares is frequently observed during initiation of anti-hyperuricemic agents, including Febustat. If a gout flare occurs during treatment, Febustat need not be discontinued. Prophylactic therapy (i.e., non-steroidal anti-inflammatory drug (NSAID) or colchicine upon initiation of treatment) may be beneficial for up to six months.
Lactation: Unknown whether drug is excreted into breast milk; use with caution
Pregnancy-Lactation
Pregnancy
Limited available data in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes
Animal data
No adverse developmental effects observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40 and 51 times, respectively, the exposure at the maximum recommended human dose (MRHD)
No adverse developmental effects observed in a pre- and postnatal development study with administration of febuxostat to pregnant rats from organogenesis through lactation at an exposure ~11 times the MRHD
Lactation
There are no data on presence of febuxostat in human milk, effects on breastfed infant, or on milk production; drug is present in rat milk
Consider the developmental and health benefits of breastfeeding along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from underlying maternal condition
Interactions
May increase plasma conc of mercaptopurine, azathioprine. Alteration of metabolism of xanthine oxidase substrate drugs (eg theophylline).
Adverse Effects
Side effects of Febuxostat :
>1%
Arthralgia, Elevated liver function test (LFT) results, Liver function abnormalities, Nausea, Rash
Mechanism of Action
Febuxostat selectively inhibits xanthine oxidase, the enzyme that catalyses the conversion of hypoxanthine to xanthine to uric acid, thereby decreasing serum concentrations of uric acid.
Note
Fiburik 80mg F / C tablet manufactured by Neopharma. Its generic name is Febuxostat. Fiburik is availble in United Arab Emirates.
Farmaco UAE drug index information on Fiburik F / C tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.